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Prostatic carcinoma (PC) is one of the most frequent cancers in men. Molecular patho-
genesis of PC remains poorly understood. Translocations involving ERG were found
to be the single most frequent genetic event. A strong correlation exists between this
translocation and ERG positivity on immunohistochemistry. The rate of ERG pos-
itivity and its relationship with other clinicopathological parameters differ between
populations and between studies; in particular, there are few data on ERG-positive
PC in Eastern Europeans. In the present study, tissue microarrays of unselected PC
cases were constructed and standard immunohistochemistry for ERG performed. The
results were compared with the basic pathologic prognostic parameters. The group
under study consisted of 113 cases; 52 (46.02%) were positive for ERG. The posi-
tive cases showed a slightly higher Gleason score (median 6 vs. 7). The majority of
ERG-positive cases showed nerve bundle invasion and were also less likely to be prostate
confined than negative ones. In conclusion, the frequency of ERG-positive PC in our
series is similar to Western populations, and they show some unfavorable prognos-
tic features.
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Introduction
Prostatic carcinoma (PC) is one of the most frequent
cancers in males in the Western world [1]; indeed it is
first in incidence in the North American population, and
second in frequency in Poland. The molecular basis of PC
remains poorly understood, and is the subject of intense
study. While most human carcinomas show complex ge-
netic changes and recurrent translocation is seen more of-
ten in leukemia or sarcomas, in 2005 it was shown that
a significant subset of PCs bear translocations involving
members of the erythroblast transformation-specific
(ETS) gene family, usually v-ets avian erythroblastosis virus
E26 oncogene homolog (ERG) [2]. Later it was shown
that ERG translocation is strongly correlated with
ERG-protein expression as detected by immunohisto-
chemistry [3-5], opening the possibility of easy studies.
The frequency of ERG translocation, its relationship
to stage, grade and prognosis, and its diagnostic utili-
ty remain a matter of debate. Interestingly, these rela-
tionships were suggested to differ between ethnic
groups; in particular ERG-positive PC is frequent in
North American and Western European populations,
but much less so in Asians [6, 7]. The differences in mo-
lecular biology of PC may depend on purely genetic fac-
tors, but also on frequency of occurrence, age structure
of the population and differences in detection strategies.
Also, the search for prognostic factors is important in
PC for distinguishing aggressive from indolent ones. One
of the potential biomarkers is angiogenesis [8], and ERG
expression could be another one. Although it may be
surmised that the PCs in Central-Eastern Europe are sim-
ilar to the cases from the Western population, hard ev-
idence is needed to support this. As no data are avail-
able on ERG positivity in Polish prostatic carcinoma
patients, we decided to perform a tissue microarray study.
Preliminary analysis of a subset of the data was pre-
sented in poster form at the 25th European Congress
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of Pathology, held in Lisbon, Portugal (31 August to
4 September 2013).
Material and methods
The material for the study consisted of unselected
prostatectomy specimens from the files of the Pathol-
ogy Department. The slides were reviewed by an uro-
logic pathologist. The cases were reclassified according
to the current Gleason system and staged according to
current TNM criteria [9, 10]. Nerve invasion, lympho-
vascular invasion, status of surgical margins, presence
of multiple tumor foci, and production of mucin were
also reevaluated. From each case one representative
section was chosen. On the slide, the region of inter-
est containing carcinoma tissue was marked, then its
extent was copied to the surface of the paraffin block.
For the tissue microarray (TMA) production a manu-
al device (Histopathology Inc., Hungary) was used. From
the region marked as cancer on each paraffin block, two
2 mm cores were obtained and transferred into a re-
cipient block. The case numbers with respective loca-
tion in the TMA were noted on an Excel (Microsoft Inc.,
USA) spreadsheet. The upper-left corner of the TMA
was left empty to allow proper orientation of the re-
sulting slides. From the TMA paraffin blocks, 2 µm sec-
tions were prepared and stained with hematoxylin-eosin
(HE) and immunohistochemistry. HE slides were used
to control the quality of tissue selection and determine
the Gleason score of specific spots. Immunohisto-
chemistry was done in the routine manner. A rabbit
monoclonal anti-ERG antibody (clone EPR3864),
produced by Abcam, was used in 1 : 200 dilution. Heat-
ing in citrate buffer for 30 minutes was used for anti-
gen retrieval. The LabVision detection system (Ther-
mo Scientific, USA) was used. The results were scored
as positive when unequivocal nuclear staining was pres-
ent; very faint nuclear and any cytoplasmic reaction were
ignored (Fig. 1). The results were collected in an Ex-
cel spreadsheet containing the case numbers. Statistics
were calculated with Statistica 10 (StatSoft Inc., USA).
Mann-Whitney U and χ2 tests were used, as appropriate.
The significance level was set to 0.05.
Results
Analyzed material consisted of 113 cases. The
mean age of the patients was 62.09 years (range 42 to
78, SD 6.53). Stage of the tumors was pT2a in 7 cas-
es (6.19%); pT2b in 3 cases (2.65%); pT2c in 34 cas-
es (30.09%); pT3a in 51 cases (45.13%); pT3b in 16
cases (14.16%); pT4 in 2 cases (1.77%). In 98 cases
(86.73%) lymph nodes contained no metastatic de-
posits; in 2 cases (1.77%) there were lymph node metas-
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Fig. 1. Immunohistochemistry for ERG in prostatic carcinoma. A, B negative cases (notice the positive reaction in
endothelia (*), C, D positive cases (notice lack of stain in non-neoplastic and stromal cells). A, C Gleason pattern 3,
B, D Gleason pattern 4. Original magnification 400×
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tases, while in 13 cases (11.50%) no lymph nodes were
sampled. In 62 cases (54.87%) the surgical margins
were negative, while in 51 cases (45.13%) positive sur-
gical margins were found.
Gleason score was 6 in 46 cases (40.71%); 7 in 54
cases (47.79%); 8 in 6 cases (5.31%); 9 in 7 cases
(6.19%). The frequency of individual Gleason patterns
is shown in Table I. Tertiary Gleason pattern was seen
in 18 cases, it was pattern 3 in 2 cases (1.77%), pat-
tern 4 in 11 cases (9.73%), and pattern 5 in 5 cases
(4.42%). Appreciable mucin production was seen in
9 cases (7.96%). Multifocality was seen in 16 cases
(14.16%). Lymphovascular invasion was seen in 39 cas-
es (34.51%) and infiltration of nerve bundles in 69 cas-
es (61.06%). In 3 cases (2.66%) intraductal carcino-
ma was present.
A positive reaction for ERG was present in 52 cases
(46.02%). The patients with ERG-positive PC were
slightly younger (61.69 years, SD 7.04 vs. 62.43 years,
SD 6.09) but this difference was not statistically sig-
nificant. The positive cases showed a higher Gleason
score (median 7 vs. 6, p < 0.05). To further explore the
relationship between Gleason grade and ERG expres-
sion, the pattern seen in individual cores was noted and
compared between immunopositive and negative
cases. Among the ERG-positive cases the proportion of
pattern 4 was significantly higher than among nega-
tive cases (41.11% vs. 23.28%, p < 0.022; Fig. 2).
ERG-positive cases were less likely to be prostate con-
fined (15 out of 52 vs. 29 out of 61 for negative cases,
p < 0.043). There were no significant differences when
considering the pT subcategories, however. The majority
of ERG-positive cases showed nerve bundle invasion
(38 out of 52 vs. 31 out of 61 for negative cases, p < 0.016).
There was no difference between ERG-positive and -
negative cases in other analyzed parameters.
Discussion
In ERG-positive PC, the translocation moves the
ERG coding sequence (or less frequently another ETS
gene family member) in the region controlled by the
androgen receptor regulatory sequence (predomi-
nantly the TMPRSS2 gene). This results in ERG mRNA
and protein overexpression. The overexpressed ERG
protein promotes cancer development and progression.
This appears to be an early event in prostatic car-
cinogenesis as, at least in some studies, ERG alterations
are seen in prostatic intraepithelial neoplasia (PIN), but
not in its putative precursor, proliferative inflamma-
tory atrophy [2, 11, 12].
To the best of our knowledge, no study concerning
ERG-positive prostatic carcinoma in the Polish pop-
ulation has been published so far. In fact, there is lit-
tle information concerning the Central Eastern Euro-
pean population. Although basically people originating
from this region are not dissimilar from Western Eu-
ropeans, some genetic differences may exist. Beside the
genetic differences, the PC in our country has a short-
er history of PSA screening and there is a smaller pop-
ulation of elderly persons. All these might influence the
frequency of ERG positivity of PC.
The prevalence of PC related to ERG alterations is
well studied in Western-European and North-Amer-
ican populations, although its relationship with prog-
nosis remains controversial. Furusato et al. reported 45%
of ERG-positive PCs [11]; they observed a strong cor-
relation between ERG expression in carcinoma and ad-
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Table I. Details of Gleason grades
GLEASON PATTERNS AND SCORES N %
3 + 3 = 6 46 40.71
3 + 4 = 7 41 36.28
3 + 5 = 8 2 1.77
4 + 3 = 7 13 11.50
4 + 4 = 8 3 2.65
4 + 5 = 9 4 3.54
5 + 3 = 8 1 0.88



























Fig. 2. Frequency of individual Gleason patterns in ERG-positive and ERG-negative TMA cores
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jacent PIN foci. ERG-positive cancers tended to show
higher grades. Van Leenders et al. [5] in biopsy mate-
rial estimated the rate of ERG positivity as 61% of cas-
es and positive tumors tended to be larger than nega-
tive ones. In the same study 73% of prostatectomy
specimens were positive; no relationship with stage or
grade was visible, yet the analyzed group was small. Also
in the preliminary analysis of the present study, and with
similar sample size to that of the van Leenders et al. study,
we were not able to detect a relationship between ERG
and grade, which became evident when the study group
expanded. Verdu et al. [13] found that 49% of Span-
ish PCs show ERG positivity. In their material no re-
lationship with Gleason grade or stage was present. Also,
they failed to see ERG expression in PIN. Szasz et al.
in a small study [14] found a positive correlation be-
tween ERG expression and Gleason grade; they also ob-
served more ERG-positive cases in advanced cancers than
in prostate-confined ones. These results are very sim-
ilar to the relationships seen in our material. Teng et al.
estimated the frequency of ERG-positive PC as 46%
[15]. Remarkably, the frequency of ERG positivity was
significantly lower in locally advanced as well as
metastatic PCs. Fine et al. [16] found 41% of TMPRSS2-
ERG translocation and an additional 9% of amplifica-
tion of the same region. Cases with translocation
showed a lower Gleason grade, while cases with am-
plification showed a higher one. Fine’s study did not an-
alyze the stage of the tumors. Albadine et al. [17] lim-
ited their analysis to low Gleason grade (< 7), prostate
confined tumors with a volume < 0.5 cm3, and com-
pared them to more advanced yet still low-grade car-
cinomas. The authors observed slightly lower frequency
of TMPRSS2-ERG fusion in minute carcinomas (47%
vs. 62%) yet the difference was not statistically signif-
icant. Also, in contrast to the present study, the fre-
quency of the ERG alteration was slightly lower in pT3
than in pT2 cases. Most importantly, Albadine et al. did
not find an association between ERG status and the risk
of biochemical recurrence [17].
The prevalence of ERG translocation in PC of Asiat-
ic patients is significantly lower. In the Korean popula-
tion, Lee et al. [7] found that only 20% of PCs were ERG-
translocation dependent, and in similar material Suh et
al. estimated this frequency as 24% [18]. What is more,
in both studies, ERG-positive cases tended to be lower
grade (Gleason score ≤ 7) and no relationship with bio-
chemical recurrence rate, age, stage or invasiveness was
observed. In particular, cancers with large cribriform
glands (typically pattern 4) were unlikely to express ERG.
In the Japanese, Kimura et al. [19] found only 16% ERG
positivity. These cases tended to be younger, lower grade
and margin-negative. Mao et al. [6] compared the ge-
netic features of PC in Chinese and British populations.
They found that in Chinese ERG translocation is quite
rare (8%). They detected no relationship between age or
Gleason grade and ERG status.
To explain the inconsistency of the relationship be-
tween ERG expression and prognosis Wu et al. [20] hy-
pothesized that the translocation seen in various cancers
may be in fact different. In some cases the ERG part-
ner of the fusion gene might be truncated, leading to
production of a protein product with no function or even
an inhibitory protein binding to ETS domain binding
sites and blocking them. This hypothesis correlates with
the different significance of translocation and amplifi-
cation of the ERG region [16]. In a recent paper, Tande-
felt et al. [21] were able to define two distinct groups
of ERG-positive PC according to gene expression
which resulted in different clinical outcomes, while ERG-
negative cases formed another cluster of cases. On the
other hand, in their study, ERG status alone was not pre-
dictive of the patients’ outcome. As pointed out by Fine
et al. [16] some problems in reporting the significance
of ERG expression for prognosis may also depend on in-
consistency in the way Gleason grade is reported. For
this reason in the present work the grading was repeated
and done by the current ISUP recommendation.
Some authors have proposed diagnostic and prog-
nostic use of ERG immunohistochemistry [5, 22-25].
The rationale for such use is very high specificity of the
translocation, its appearance early in the course of dis-
ease and persistence in the course of cancer progression.
In fact, ERG positivity was not described in cases of pro-
static cancer mimickers. On the other hand, ERG pos-
itivity is obviously a low-sensitivity test. In our opin-
ion, for the time being, extreme caution is needed in
diagnostic use of ERG immunohistochemistry. Also, the
prevalence of ERG positivity in PC with extraprosta-
tic extension and higher grade might make it useful
for distinguishing aggressive and indolent carcinomas.
Unfortunately, the relationship seen in this and a few
other studies is not confirmed by other authors.
In conclusion, we have shown for the first time that
prostatic carcinoma in Polish patients shows a similar
rate of ERG expression to patients of Western Euro-
pean descent. Our ERG-positive cases also tend to dis-
play unfavorable prognostic factors such as higher stage
and grade.
The authors declare no conflict of interest.
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